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In severe cases of coronavirus disease 2019 (COVID-19), viral pneumonia progresses to respiratory
failure. Neutrophil extracellular traps (NETs) are extracellular webs of chromatin, microbicidal
proteins, and oxidant enzymes that are released by neutrophils to contain infections. However,
when not properly regulated, NETs have the potential to propagate inflammation and microvascular
thrombosis — including in the lungs of patients with acute respiratory distress syndrome.
We now report that sera from patients with COVID-19 have elevated levels of cell-free DNA,
myeloperoxidase-DNA (MPO-DNA), and citrullinated histone H3 (Cit-H3); the latter 2 are specific
markers of NETs. Highlighting the potential clinical relevance of these findings, cell-free DNA
strongly correlated with acute-phase reactants, including C-reactive protein, D-dimer, and lactate
dehydrogenase, as well as absolute neutrophil count. MPO-DNA associated with both cell-free
DNA and absolute neutrophil count, while Cit-H3 correlated with platelet levels. Importantly, both
cell-free DNA and MPO-DNA were higher in hospitalized patients receiving mechanical ventilation
as compared with hospitalized patients breathing room air. Finally, sera from individuals with
COVID-19 triggered NET release from control neutrophils in vitro. Future studies should investigate
the predictive power of circulating NETs in longitudinal cohorts and determine the extent to which
NETs may be novel therapeutic targets in severe COVID-19.
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As of late May 2020, the coronavirus disease 2019 (COVID-19) pandemic has affected more than 5 million
individuals from over 180 countries and has resulted in unprecedented health, social, and economic crises
(1). The disease is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), manifesting with flu-like symptoms and a viral pneumonia that progresses to acute respiratory distress syndrome
(ARDS) and even multiorgan failure in some individuals (2).
Elevated levels of blood neutrophils are an early indicator of SARS-CoV-2 infection, predicting severe
respiratory disease and worse outcomes (3, 4). Over the past decade, our group and many others have
revealed a pathogenic role for neutrophil-derived neutrophil extracellular traps (NETs) in various thrombo-inflammatory states, including sepsis (5, 6), thrombosis (7–9), and respiratory failure (10, 11). NETs are
extracellular webs of DNA, histones, microbicidal proteins, and oxidant enzymes that are released by neutrophils to corral infections; however, when not properly regulated, NETs have the potential to initiate and
propagate inflammation and thrombosis (12, 13). Indeed, inhibition of neutrophils and NETs is protective
in various models of influenza-associated ARDS (14–17). Although it has yet to be assessed whether NETs
contribute to the inflammatory storm that leads to respiratory failure in many patients with COVID-19,
there is emerging evidence to implicate inflammatory cytokines, such as IL-1β and IL-6, in the COVID-19
milieu (18). Not surprisingly, NETs are intimately intertwined with both cytokines, and especially IL-1β, in
many pulmonary and cardiovascular diseases (9, 19–24).
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Other pandemic viruses, including influenza H1N1, SARS-CoV, and Middle East respiratory syndrome coronavirus, are associated with neutrophilic infiltration at sites of infection and development of
ARDS (25, 26). The acute, exudative phase of ARDS is characterized by an exuberant immune response
producing proinflammatory cytokines and chemokines, increased neutrophil infiltration and accumulation
in the alveoli, and disruption of the alveolar epithelial-capillary barrier (27). Culturing neutrophils in vitro
with influenza-infected lung epithelial cells triggers NETosis and augments endothelial damage by culture
supernatants (14). Neutrophil-depleted mice demonstrate milder lung pathology in response to influenza infection, including lower levels of thrombomodulin, matrix metalloproteinases, and myeloperoxidase
(MPO) in bronchoalveolar lavage fluid (14). At the same time, influenza-infected mice are protected by
strategies that prevent NETosis including inhibition of superoxide dismutase (14) and MPO (14, 28). In
patients with influenza A infection, high levels of NETs predict a poor prognosis (29).
Work to date exploring the pathophysiology of COVID-19 has focused especially on macrophages and
epithelial cells, with little attention paid to neutrophils and their catalysts, checkpoints, and effector mechanisms — all of which could add actionable context to our understanding of the COVID-19 inflammatory
storm. Here, as a first step toward assessing the role of NETs in COVID-19, we sought to measure various
markers of NETs in sera of hospitalized patients and to determine their relationship to severity of illness.

Results
Detection of NETs in sera of COVID-19 patients. Serum samples were obtained from 50 patients hospitalized
with COVID-19 at a large academic hospital (Table 1). As compared with serum samples from 30 healthy
controls, the COVID-19 samples showed higher levels of cell-free DNA (Figure 1A), MPO-DNA complexes (Figure 1B), and citrullinated histone H3 (Cit-H3, Figure 1C). The latter 2 markers are generally
regarded as specific for NET remnants. While cell-free DNA and MPO-DNA demonstrated a significant
correlative relationship (Figure 1D), the association between cell-free DNA and Cit-H3 was not significant
(Figure 1E). For a subset of the patients (n = 22), longitudinal serum samples were available. Three of those
patients showed worsening oxygenation during the period of collection (room air to nasal cannula oxygen,
nasal cannula oxygen to high-flow oxygen, and room air to mechanical ventilation, respectively). For all
3, markers of NETs trended up as oxygenation worsened (Supplemental Figure 1; supplemental material
available online with this article; https://doi.org/10.1172/jci.insight.138999DS1). All available samples
(n = 84) were included in the subsequent correlation analyses. In summary, 3 markers indicative of NET
remnants were elevated in sera of patients with COVID-19 as compared with controls.
Association between NETs and clinical biomarkers. Given that circulating NETs may be drivers of, or form
in response to, other blood products, we next asked how the aforementioned NET markers compared with
several commonly available clinical tests. Specifically, we assessed potential correlations with C-reactive protein, D-dimer, lactate dehydrogenase, absolute neutrophil count, and platelet count. To draw integral comparisons, we limited the analysis of clinical laboratory measurements to those performed on the same day as
serum used for NET assays. Cell-free DNA demonstrated a strong positive correlation with all the clinical
tests other than platelet count (Figure 2, A–D). When we compared the clinical labs with MPO-DNA, we
detected a strong positive correlation with absolute neutrophil count (Figure 2E), while C-reactive protein
(r = 0.10, P = 0.44), D-dimer (r = 0.05, P = 0.72), and lactate dehydrogenase (r = 0.17, P = 0.22) demonstrated positive slopes that were not statistically significant. Interestingly, Cit-H3 levels were positively correlated
with platelet counts (Figure 2F) but not the other clinical laboratory measurements. All available samples
(n = 84) were included in the correlation analyses of Figure 2. When including only the first available sample
from each patient (n = 50), correlations were similar (Supplemental Figure 2). Approximately half of the
patients were treated with hydroxychloroquine (Table 1). We did not find a difference in NET markers from
samples collected on days of hydroxychloroquine administration versus days without (Supplemental Figure
3). In summary, cell-free DNA and to a lesser extent MPO-DNA and Cit-H3 demonstrated significant correlations with clinical studies routinely used in the care of patients with COVID-19.
NETs associate with severe disease including mechanical ventilation. We next determined the clinical status
associated with each available serum sample. We compared samples from patients with severe COVID-19
(those requiring mechanical ventilation, n = 27 samples) with patients with milder COVID-19 (oxygen
saturation > 94% on ambient air, n = 24 samples). As compared with patients breathing room air, patients
requiring mechanical ventilation had significantly higher levels of cell-free DNA (Figure 3A) and MPODNA (Figure 3B) but not Cit-H3 (Figure 3C). Absolute neutrophil counts were not significantly higher in
insight.jci.org   https://doi.org/10.1172/jci.insight.138999
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Table 1. COVID-19 patient characteristics
Demographics

Number
Age (years)A
Hospital dayB,C
Female
White
Black/African-American
Comorbidities
Diabetes
Heart disease
Renal disease
Lung disease
Autoimmune
Cancer
History of stroke
Obesity
Hypertension
Immune deficiency
History of smoking
MedicationsC
Hydroxychloroquine
Anti–IL-6 receptor
ACE inhibitor
Angiotensin receptor blocker
Antibiotic
Antiviral
Respiratory statusC
Mechanical ventilation
High-flow oxygen
Nasal cannula oxygen
Room air

50
61 ± 15
3.7 ± 4.1
17
19
29

(range 29–91)
(range 1–25)
(34%)
(38%)
(18%)

16
12
16
17
4
10
3
23
37
3
18

(32%)
(24%)
(32%)
(34%)
(8%)
(20%)
(6%)
(46%)
(74%)
(6%)
(36%)

24
2
1
0
22
0

(48%)
(4%)
(2%)
(0%)
(44%)
(0%)

16
2
17
15

(32%)
(4%)
(34%)
(30%)

Mean ± standard deviation. BMedian = 2. CAt time of first sample available for testing. ACE, angiotensin converting
enzyme.
A

the ventilated patients (Figure 3D). Taken together, these data suggest a possible relationship between level
of serum NETs and severity of COVID-19.
COVID-19 sera trigger control neutrophils to release NETs. If COVID-19 presents a milieu favoring NETosis,
we reasoned that direct exposure of control neutrophils to patient sera (without any additional agonist)
would trigger these healthy neutrophils to undergo NETosis. As compared with heterologous control sera,
the patient sera robustly promoted NETosis whether measured by externalization of DNA (Figure 4A) or
release of DNA-bound MPO enzyme (Figure 4B). Immunofluorescence microscopy demonstrated extracellular chromatin structures decorated with neutrophil elastase characteristic of NETs (Figure 4C). In summary, serum samples from patients with COVID-19 robustly triggered healthy neutrophils to undergo NETosis.

Discussion
Here, we report for the first time to our knowledge elevated levels of serum NETs in many hospitalized patients
with COVID-19. We measured 3 markers commonly used to detect NET remnants in blood (cell-free DNA,
MPO-DNA, and Cit-H3) and found significant elevations in all 3. We also found that COVID-19 sera are
potent stimulators of NETosis when added to control neutrophils. Taken together, these data provide evidence
that COVID-19, at least in hospitalized patients, is a pro-NETotic state. The triggers of NETosis in COVID-19
are potentially myriad and will require further investigation. Possibilities include virus-damaged epithelial cells
(14, 30), activated platelets (31, 32), activated endothelial cells (33), and inflammatory cytokines, such as IL-1β
(20, 34), IL-8 (35, 36), granulocyte colony-stimulating factor (37, 38), and likely others (18).
insight.jci.org   https://doi.org/10.1172/jci.insight.138999

3

RESEARCH ARTICLE

Figure 1. Detection of NETs in sera of COVID-19 patients. Sera from COVID-19 patients (n = 50) and healthy controls
(n = 30) were assessed for cell-free DNA (A), myeloperoxidase-DNA (MPO-DNA) complexes (B), or citrullinated histone
H3 (Cit-H3) (C). COVID-19 samples were compared with controls by Mann-Whitney U test; ***P < 0.001, ****P < 0.0001.
For the COVID-19 samples, correlation of cell-free DNA with MPO-DNA (D) and Cit-H3 (E) was assessed. Spearman’s
correlation coefficients were calculated and are shown in the panels.

Of the markers we tested, cell-free DNA was most closely aligned with traditional inflammatory markers used to track COVID-19, including C-reactive protein, D-dimer, and lactate dehydrogenase. Notably,
although cell-free DNA is not a highly specific marker for NETs, it was strongly correlated with absolute
neutrophil count, as was the more specific marker of NETs, MPO-DNA. Somewhat unexpectedly, Cit-H3
did not correlate well with the other 2 markers but did associate strongly with platelet levels. It is believed
that the predominant driver of histone citrullination (i.e., production of Cit-H3) in NETs is the enzyme
peptidylarginine deiminase 4 (PAD4) (39). However, neutrophils can be triggered to undergo NETosis by
a variety of stimuli, and in vitro studies demonstrate that not all pathways to NETosis are equally reliant on PAD4 activity (40); for example, stimuli that lead to robust reactive oxygen species production
may be relatively PAD4 independent (41). The dichotomy between MPO-DNA and Cit-H3 levels in the
COVID-19 sera tested here potentially suggests that 2 or more pathways to NETosis are active in patients
with COVID-19, with the pathway leading to Cit-H3 perhaps having some relationship to platelets (42). It
should also be noted that neutrophils are relatively short-lived cells that may experience cell death through
many pathways, including apoptosis, necrosis, pyroptosis, NETosis, and others. Markers such as lactate
dehydrogenase, cell-free DNA, and Cit-H3 may therefore also be produced by neutrophil cell death that is
independent of NETosis (43, 44). The activation of other cell death programs, and their relationship to the
inflammatory storm, certainly warrant further investigation in COVID-19.
NETs were first described in 2004 as a novel pathogen eradication strategy that could function as an
alternative to phagocytosis (36), but it is now recognized that NETs have double-edged-sword properties
and likely exacerbate (and in some cases even initiate) autoimmune and vascular diseases (45). NETs
present and stabilize a variety of oxidant enzymes in the extracellular space, including MPO, NADPH
oxidase, and nitric oxide synthase (46), while serving as a source of extracellular histones that carry
significant cytotoxic potential (47, 48). In light of these toxic cargo, it is not surprising that NETs play
a role in a variety of lung diseases, including cystic fibrosis (where they occlude larger airways) (49),
insight.jci.org   https://doi.org/10.1172/jci.insight.138999

4

RESEARCH ARTICLE

Figure 2. Association between NETs and clinical biomarkers in all available serum samples. Cell-free DNA was compared with clinical laboratory results (when available on the same day), and correlation coefficients were calculated for
C-reactive protein (A, n = 64), D-dimer (B, n = 56), lactate dehydrogenase (C, n = 55), and absolute neutrophil count (D,
n = 69). In E (n = 69), MPO-DNA was compared with absolute neutrophils count, and in F (n = 81), Cit-H3 was compared
with platelet count. The results of other relevant comparisons are discussed in the text. Pearson’s correlation coefficients were calculated and are shown in the panels.

smoking-related lung disease (50), and, with particular relevance here, pathogen-induced acute lung
injury and ARDS (14, 51, 53). NETs have also been very well studied in the setting of cardiovascular
disease, where they infiltrate and propagate inflammation in the vessel wall (53) and, when formed intravascularly, occlude arteries (54), veins (55), and microscopic vessels (56). Early studies of COVID-19
suggest a high risk of morbid arterial events (57), and one can speculate that the risk of venous thrombosis will increasingly reveal itself as more data become available (58).
Severe COVID-19 appears to be defined by neutrophilia, as well as elevations in IL-1β, IL-6, and
D-dimer (18), the latter suggesting hyperactivity of the coagulation system. All these findings have significant potential for crosstalk with NETs. NETs are linked to IL-1β (both upstream and downstream) in
cardiovascular and pulmonary diseases (19–22), including as described by our group for venous thrombosis (9). The same is true for IL-6, either directly (23), or perhaps with IL-1β as an intermediary (24).
Of course, as discussed above, examples of NETs as drivers of thrombosis are myriad because intravascular NETosis is responsible for initiation and accretion of thrombotic events in arteries, veins, and
insight.jci.org   https://doi.org/10.1172/jci.insight.138999
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Figure 3. Levels of NETs associate with mechanical ventilation in all available serum samples. Serum samples were
grouped by clinical status (room air versus mechanical ventilation) and analyzed for cell-free DNA (A, n = 51), MPODNA complexes (B, n = 51), Cit-H3 (C, n = 51), and absolute neutrophil count (D, n = 42). Groups were compared by
Mann-Whitney U test; ****P < 0.0001, *P < 0.05. For D, the P value was 0.08.

— particularly pertinent to COVID-19 — the microvasculature, where thrombotic disease can drive end
organ damage in lungs, heart, kidneys, and other organs (59, 60). Mechanistically, NETs, via electrostatic interactions, activate the contact pathway of coagulation (61), while presenting tissue factor to activate
the intrinsic pathway (62). Simultaneously, serine proteases in NETs dismantle natural brakes on coagulation, such as tissue factor pathway inhibitor and antithrombin (63). Bidirectional interplay between
NETs and platelets may also be critical for COVID-19–associated microvascular thrombosis, as has been
characterized in a variety of disease models (60, 61).
Of interest, a recent small study performed in China suggested potential efficacy of the adenosine receptor agonist, dipyridamole, in severe cases of COVID-19 (64). Dipyridamole is an FDA-approved drug that our group recently discovered to inhibit NET formation by activation of adenosine
A2A receptors (7). In the aforementioned trial, patients with COVID-19–associated bilateral pneumonia
were treated with oral dipyridamole for 7 days, in addition to treatment with antiviral agents (64). As
compared with controls, dipyridamole-treated patients demonstrated improvements in platelet counts
and D-dimer levels (64). Given the urgent need for effective treatments for COVID-19, a randomized
study to characterize the impact of dipyridamole on COVID-19–related NETosis, thrombo-inflammatory storm, and, of course, outcomes may be warranted. Other approaches to combating NETs have been
reviewed (65, 66) and include the dismantling of already-formed NETs (deoxyribonucleases) and strategies that might prevent initiation of NET release, including inhibitors of neutrophil elastase and PAD4.
This study is not without limitations, including the use of serum samples retrieved from the clinical laboratory, rather than samples drawn specifically for research purposes. Here, it is certainly possible that NETs were partially degraded over time, thereby lowering our measurements. It should also
be emphasized that it is not clear whether the NET remnants described here are drivers of disease
severity or a mere consequence of acute inflammation in patients. Indeed, the definitive accounting of
COVID-19 pathophysiology and answering questions of causality will likely await the development of
model systems. Our hope, though, is that these findings will ignite further research into the role of neutrophil effector functions in the complications of COVID-19 (67). As a first step, future studies should
insight.jci.org   https://doi.org/10.1172/jci.insight.138999
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Figure 4. COVID-19 sera trigger control neutrophils to release NETs. COVID-19 samples (for which sufficient sera were
available) were tested for their ability to trigger neutrophils isolated from healthy controls to undergo NETosis. (A)
NETosis was quantified using the cell-impermeant dye SYTOX Green as described in Methods (n = 27 COVID-19 samples, and n = 20 controls). Fluorescence intensity (excitation/emission 504 nm/523 nm) is shown on the y axis. Bars
demonstrate mean and standard deviation while each data point represents a unique patient/control; ***P < 0.001
by t test. (B) In an independent set of experiments, NETosis was quantified as nuclease-liberated MPO activity (n =
27 COVID-19 samples, and n = 17 controls). Absorbance at 450 nm is shown on the y axis after subtracting background
from untreated cells. Bars demonstrate mean and standard deviation while each data point represents a unique
patient/control; **P < 0.01 by t test. (C) Representative image of control neutrophils cultured with 10% heterologous
control serum (upper) or COVID-19 serum (lower). Neutrophil elastase is stained green and DNA is stained blue. Scale
bar: 100 μm. The yellow arrows highlight some examples of NET strands.

investigate the predictive power of circulating NETs in well-phenotyped longitudinal cohorts. Furthermore, given the dichotomy we found here between MPO-DNA and Cit-H3, investigators should be
encouraged to continue to include diverse markers of NETosis in future studies. As we await definitive
antiviral and immunological solutions to the current pandemic, we posit that antineutrophil therapies
may be part of a personalized strategy for some individuals affected by COVID-19 who are at risk for
progression to respiratory failure.
insight.jci.org   https://doi.org/10.1172/jci.insight.138999
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Methods
Human samples. Serum samples from 50 hospitalized COVID-19 patients (84 total samples) were used in
this study. Blood was collected into serum separator tubes containing clot activator and serum separator gel
by a trained hospital phlebotomist. After completion of biochemical testing ordered by the clinician, the
remaining serum was stored at 4°C for up to 48 hours before it was deemed “discarded” and released to the
research laboratory. Serum samples were immediately divided into small aliquots and stored at –80°C until
the time of testing. All 50 patients had a confirmed COVID-19 diagnosis based on FDA-approved RNA
testing. This study complied with all relevant ethical regulations and was approved by the University of
Michigan Institutional Review Board (HUM00179409), which waived the requirement for informed consent given the discarded nature of the samples. Healthy volunteers were recruited through a posted flyer;
exclusion criteria for these controls included history of a systemic autoimmune disease, active infection,
and pregnancy. For preparation of control serum, blood was collected into serum separator tubes containing clot activator and serum separator gel by a trained hospital phlebotomist. Samples were centrifuged at
approximately 2000 g, similar to the clinical samples. These serum samples were divided into small aliquots
and stored at –80°C until the time of testing.
Quantification of cell-free DNA. Cell-free DNA was quantified in sera using the Quant-iT PicoGreen dsDNA Assay Kit (Invitrogen, Thermo Fisher Scientific, P11496) according to the manufacturer’s instructions.
Quantification of Cit-H3. Cit-H3 was quantified in sera using the Citrullinated Histone H3 (clone 11D3)
ELISA Kit (Cayman, 501620) according to the manufacturer’s instructions.
Quantification of MPO-DNA complexes. MPO-DNA complexes were quantified similarly to what has
been previously described (68). This protocol used several reagents from the Cell Death Detection ELISA kit (Roche). First, a high-binding EIA/RIA 96-well plate (Costar) was coated overnight at 4°C with
anti-human MPO antibody (Bio-Rad 0400-0002), diluted to a concentration of 1 μg/mL in coating buffer
(Cell Death kit). The plate was washed 2 times with wash buffer (0.05% Tween-20 in PBS), then blocked
with 4% bovine serum albumin (MilliporeSigma) in PBS (supplemented with 0.05% Tween-20) for 2 hours
at room temperature. The plate was again washed 5 times, before incubating for 90 minutes at room temperature with 10% serum or plasma in the aforementioned blocking buffer (without Tween-20). The plate
was washed 5 times, then incubated for 90 minutes at room temperature with 10× anti-DNA antibody
(HRP conjugated; from the Cell Death kit) diluted 1:100 in blocking buffer. After 5 more washes, the plate
was developed with 3,3′,5,5′-Tetramethylbenzidine (TMB) substrate (Invitrogen, Thermo Fisher Scientific)
followed by a 2N sulfuric acid stop solution. Absorbance was measured at a wavelength of 450 nm using
a Cytation 5 Cell Imaging Multi-Mode Reader (BioTek). Data were normalized to in vitro–prepared NET
standards included on every plate, which were quantified based on their DNA content.
Human neutrophil purification. For neutrophil preparation, blood from healthy volunteers was collected
into sodium citrate tubes by standard phlebotomy techniques. The anticoagulated blood was then fractionated by density-gradient centrifugation using Ficoll-Paque Plus (GE Healthcare). Neutrophils were further
purified by dextran sedimentation of the red blood cell layer, before lysing residual red blood cells with 0.2%
sodium chloride. Neutrophil preparations were at least 95% pure as confirmed by nuclear morphology.
NETosis assay (SYTOX Green). A cell-impermeant dye, SYTOX Green (Thermo Fisher Scientific), was used to measure NETosis. Briefly, purified neutrophils were resuspended in 1× PBS (Gibco,
Thermo Fisher Scientific). One hundred thousand neutrophils were seeded into each well of a 0.001%
poly-l-lysine–coated (MilliporeSigma), 96-well, black, clear-bottom non-tissue culture plate (Costar)
and were allowed to adhere for 20 minutes at 37°C and 5% CO2. PBS was gently removed and control/
patient serum (diluted to 10% in RPMI culture medium from Thermo Fisher Scientific, supplemented
with l-glutamine) was carefully added without disrupting adherent cells. SYTOX Green was added at
the same time to a final concentration of 500 nM. All treatments were done in triplicate. Cells were
allowed to undergo NETosis for 4 hours. Culture medium was then gently removed, and fresh 1×
PBS was added to each well. Fluorescence was quantified at excitation and emission wavelengths of
504 nm and 523 nm, respectively, using a Cytation 5 Cell Imaging Multi-Mode Reader (BioTek). Data
were collected using the area-scan setting of the plate reader.
NETosis assay (NET-associated MPO). Purified neutrophils were resuspended in RPMI medium
(Gibco, Thermo Fisher Scientific) supplemented with 0.5% bovine serum albumin (MilliporeSigma),
0.5% heat-inactivated fetal bovine serum (FBS, Gibco, Thermo Fisher Scientific), and l-glutamine.
Neutrophils (1 × 105/well) were cultured in a 96-well tissue culture plate (Costar) in the presence of
insight.jci.org   https://doi.org/10.1172/jci.insight.138999
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either patient or control serum, diluted to a final concentration of 10%. Plates were incubated for 3
hours at 37°C and 5% CO2. To collect NET-associated MPO, the culture medium was discarded (to
remove any soluble MPO) and replaced with 100 μL of PBS supplemented with 5 U/mL Micrococcal
Nuclease (Thermo Fisher Scientific). After 10 minutes at 37°C, digestion of NETs was stopped with
10 mM EDTA. Supernatants were transferred to a V-shaped, 96-well plate, and centrifuged at 400 g for
5 minutes to remove debris. Supernatants were then transferred into a new flat-bottom, 96-well plate.
To quantify MPO activity, an equal volume of TMB substrate (Thermo Fisher Scientific) was added to
each well. After 10 minutes of incubation in the dark, the reaction was stopped by the 2N sulfuric acid
solution. Absorbance was measured at 450 nm using a Cytation 5 Cell Imaging Multi-Mode Reader.
NETosis assay (microscopy). For immunofluorescence microscopy, 1 × 105 neutrophils were seeded onto
coverslips coated with 0.001% poly-l-lysine (MilliporeSigma) and cultured as for the above assays. Samples
were then fixed with 4% paraformaldehyde for 10 minutes at room temperature, followed by blocking with
10% FBS in PBS. The primary antibody was against neutrophil elastase (Abcam 21595, diluted 1:100), and
the FITC-conjugated secondary antibody was from SouthernBiotech (4052-02, diluted 1:250). DNA was
stained with Hoechst 33342 (Invitrogen, Thermo Fisher Scientific). Images were collected with a Cytation
5 Cell Imaging Multi-Mode Reader.
Statistics. Normally distributed data were analyzed by 2-sided t test, and skewed data were analyzed
by Mann-Whitney U test. Data analysis was with GraphPad Prism software version 8. Correlations were
tested by Pearson’s or Spearman’s correlation coefficient as indicated. Statistical significance was defined as
P < 0.05 unless stated otherwise.
Study approval. The study was approved by the University of Michigan Institutional Review Board
(HUM00179409), which waived the requirement for informed consent given the discarded nature of the
patient samples. Healthy volunteers were recruited under University of Michigan protocol HUM00044257
and provided informed consent.
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